ES2023552A6 - Procedimiento para la preparacion de compuestos de inclusion de nimesulida con ciclodextrina. - Google Patents

Procedimiento para la preparacion de compuestos de inclusion de nimesulida con ciclodextrina.

Info

Publication number
ES2023552A6
ES2023552A6 ES9001566A ES9001566A ES2023552A6 ES 2023552 A6 ES2023552 A6 ES 2023552A6 ES 9001566 A ES9001566 A ES 9001566A ES 9001566 A ES9001566 A ES 9001566A ES 2023552 A6 ES2023552 A6 ES 2023552A6
Authority
ES
Spain
Prior art keywords
nimesulid
cyclodextrin
cpds
soluble
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9001566A
Other languages
English (en)
Inventor
Girona Isidro Sicart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PATPHARM HOLDING, S.A.
Original Assignee
LEETRIM Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEETRIM Ltd filed Critical LEETRIM Ltd
Priority to ES9001566A priority Critical patent/ES2023552A6/es
Priority to ITMI911396A priority patent/IT1255982B/it
Priority to DE4116659A priority patent/DE4116659C2/de
Priority to FR9106165A priority patent/FR2662360B1/fr
Publication of ES2023552A6 publication Critical patent/ES2023552A6/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTOS PARA LA PREPARACION DE COMPUESTOS DE INCLUSION DE NIMESULIDA CON CILODEXTRINA. UN PRIMER PROCEDIMIENTO CONSISTE EN HACER REACCIONAR UNA SOLUCION ACUOSA DE CICLODEXTRINA CON UNA SOLUCION ORGANICA DE NIMESULIDA, Y EN AISLAR EL COMPUESTO DE INCLUSION POR FILTRACION. UN SEGUNDO PROCEDIMIENTO CONSISTE EN HACER REACCIONAR LA NIMESULIDA Y LA CICLODEXTRINA EN UNA SOLUCION AMONIACAL Y EN AISLAR EL COMPUESTO DE INCLUSION POR SECADO DE LA SOLUCION. UN TERCER PROCEDIMIENTO CONSISTE EN HACER REACCIONAR LA NIMESULIDA Y LA CICLODEXTRINA EN UNA SOLUCION AMONIACAL, Y EN AISLAR EL COMPUESTO DE INCLUSION POR LIOFILIZACION. CON DICHOS PROCEDIMIENTOS SE OBTIENEN COMPUESTOS DE INCLUSION DE NIMESULIDA CON CICLODEXTRINA ALFA, BETA Y GAMMA SUSTITUIDA O EN SU FORMA HIDRATADA EN RELACION MOLECULAR NIMESULIDA/CICLODEXTRINA COMPRENDIDA ENTRE 1:0,5 Y 1:15.
ES9001566A 1990-05-22 1990-05-22 Procedimiento para la preparacion de compuestos de inclusion de nimesulida con ciclodextrina. Expired - Fee Related ES2023552A6 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES9001566A ES2023552A6 (es) 1990-05-22 1990-05-22 Procedimiento para la preparacion de compuestos de inclusion de nimesulida con ciclodextrina.
ITMI911396A IT1255982B (it) 1990-05-22 1991-05-21 Composti di inclusione di nimesulide con ciclodestrina e procedimento per la preparazione di tali composti
DE4116659A DE4116659C2 (de) 1990-05-22 1991-05-22 Nimesulid-Einschlußverbindungen mit Cyclodextrin, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
FR9106165A FR2662360B1 (fr) 1990-05-22 1991-05-22 Composes d'inclusion de nimesulide avec la cyclodextrine, procedes pour la preparation de ces composes et compositions pharmaceutiques a activite analgesique et anti-inflammatoire les contenant.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9001566A ES2023552A6 (es) 1990-05-22 1990-05-22 Procedimiento para la preparacion de compuestos de inclusion de nimesulida con ciclodextrina.

Publications (1)

Publication Number Publication Date
ES2023552A6 true ES2023552A6 (es) 1992-01-16

Family

ID=8267635

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9001566A Expired - Fee Related ES2023552A6 (es) 1990-05-22 1990-05-22 Procedimiento para la preparacion de compuestos de inclusion de nimesulida con ciclodextrina.

Country Status (4)

Country Link
DE (1) DE4116659C2 (es)
ES (1) ES2023552A6 (es)
FR (1) FR2662360B1 (es)
IT (1) IT1255982B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1255462B (it) * 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
IT1291278B1 (it) * 1996-07-05 1999-01-07 Errekappa Euroterapici S P A Preparazione farmaceutica a base di nimesulide per uso topico
IN186315B (es) * 1996-12-12 2001-08-04 Panacea Biotec Ltd
IT1291895B1 (it) * 1997-04-24 1999-01-21 Errekappa Euroterapici S P A Preparazione farmaceutica fluida a base di nimesulide per uso orale e rinofaringeo
CN101431992A (zh) * 2006-04-24 2009-05-13 万能药生物有限公司 包含尼美舒利的新型低剂量药物组合物及其制备和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR206496A1 (es) * 1972-07-03 1976-07-30 Riker Laboratories Inc Procedimiento para la preparacion de 2-fenoxi-4-nitro-alquil o haloalquilsulfonanilidas
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
FR2662360A1 (fr) 1991-11-29
DE4116659C2 (de) 2000-11-16
DE4116659A1 (de) 1991-11-28
IT1255982B (it) 1995-11-17
ITMI911396A0 (it) 1991-05-21
ITMI911396A1 (it) 1992-11-21
FR2662360B1 (fr) 1993-07-30

Similar Documents

Publication Publication Date Title
EP1007082A4 (en) MODIFIED TUMOR NEKROSIS FACTOR
PT620828E (pt) Derivados de ciclodextrinas que exibem uma melhor solubilidade em agua e sua utilizacao
ATE246514T1 (de) Paclitaxel enthaltende arzneimittel
HUT77886A (hu) Ondansetront tartalmazó, fagyasztva szárított készítmények
TWI265808B (en) Valdecoxib compositions
CY1110988T1 (el) Ταχεως αποσαθρουμενο στερεο παρασκευασμα
TW366342B (en) The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
MY106272A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
NO962088L (no) Preparat for in vivo-produksjon av terapeutiske produkter
MY119403A (en) Novel compounds with analgesic effect.
DE69737995D1 (de) INSULINPREPARATION MIT MAnnitol
IL146125A0 (en) Novel quinones as disease therapies
IT1269578B (it) Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
IT1255723B (it) Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
ATE201984T1 (de) Pharmazeutische zubereitungen enthaltend cefaclor
PT866791E (pt) Diaminopirimidinas formulacoes farmaceuticas que as contem e sua utilizacao antibacteriana
GR3015431T3 (en) Use of acetyl L-carnitine in the therapeutic treatment of coma.
DE60006788D1 (de) Iod-herstellungszusammensetzung
FI102462B1 (fi) Menetelmä nimesulidin syklodekstriinikompleksin valmistamiseksi
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
GEP20043313B (en) Use of Pharmaceutical Composition for Treatment of Endometriosis or Infertility, or Improving Fertility
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
NO960347D0 (no) Anvendelse av benzydamid ved behandling av patologiske tilstander forårsaket av TNF
GEP20074097B (en) Use of specific dose of fondaparinux sodium for the treatment of acs
ES2074418T3 (es) Procedimiento para la solubilizacion de la poli(1-3)glucopiranosa.

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: PATPHARM HOLDING, S.A.

FD1A Patent lapsed

Effective date: 20050523